Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis

Mia E. Koponen [1,*], Dhaneesha N. S. Senaratne [1], Harry L. Hébert [1], Blair H. Smith [1], Lesley A. Colvin [1]

[1] Chronic Pain Research Group, Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK

*Corresponding author: ME Koponen, 180014378@dundee.ac.uk, Chronic Pain Research Group, University of Dundee, Level 7 Corridor E, Ninewells Hospital, Dundee, DD1 9SY, UK

Abstract

Background: Pharmacoepidemiological studies show that large proportions of people with neuropathic pain (NP) are not prescribed the medications recommended for NP, do not adhere well to these medications, and/or often discontinue the treatment within half a year. Identifying what predicts these outcomes can inform a strategy to ensure that people with NP are prescribed recommended medication and continue their treatment when appropriate.

Methods: We carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with NP (PROSPERO ID: CRD42023464307). Electronic searches were conducted in Embase, PubMed, Web of Science, and CINAHL Plus.

Results: We identified 60 relevant studies and divided them into non-mutually exclusive categories based on the outcomes they had investigated. There were 45 studies on prescribing, 14 on adherence, and 25 on discontinuation. Predictors associated with being prescribed recommended NP medications as the first choice included white ethnicity, having diabetes, and/or having a mental health disorder. Predictors associated with better adherence included being prescribed serotonin-norepinephrine reuptake inhibitors compared to gabapentinoids or tricyclic antidepressants; dose titration, and/or implementing a medicine reminder. Predictors associated with a higher likelihood of discontinuation included being prescribed medications other than second-generation antidepressants and/or having a combination of NP medications rather than a single medication.

Conclusions: Thus, there is a need to focus on improving NP medication prescribing for ethnic minorities and people with non-diabetic NP. Adherence and persistence with NP medications could be improved by prioritising the prescribing of serotonin-norepinephrine reuptake inhibitors if indicated.

Keywords

Meta-analysis; neuropathic pain; pain medicine; pharmacoepidemiology; prescribing; systematic review; treatment adherence; treatment persistence

1. Introduction

Neuropathic pain (NP) is 'pain that arises as a direct consequence of a lesion or disease affecting the somatosensory system' and is associated with unpleasant sensations including those described as burning, pins and needles, electric shocks, and numbness.[1, 2] NP affects 7%-10% of the general population and has a substantial negative effect on people's quality of life even compared to those experiencing other types of chronic pain.[3–6] In addition, common analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids that are used to treat nociceptive pain may be ineffective in treating neuropathic pain.[7–9] The international pharmacotherapy guidelines for NP are currently being updated, but in the previous version from 2015 the first-line medications for NP are gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs).[7] Second-line NP medications include tramadol, lidocaine, or capsaicin; and third-line medications include botulinum toxin A or strong opioids.

Despite the existing treatment guidelines and variety of choices, studies suggest that there are major inconsistencies in NP treatment. For example, in a retrospective cohort study conducted in the USA during 2001-2014, only 52.9% of 14,426 people with NP were prescribed a first-line medication in the year before or three years after diagnosis.[10] This suggests that a large proportion of people with NP are not being prescribed recommended treatment. Another retrospective cohort study conducted in the USA during 2001-2016 showed that in a sample of 57,495 people with NP, adherence to gabapentinoids and SNRIs was on average ~40-50% and ~50-60% respectively,[11] which suggests that adherence to NP medications is moderate or poor.[12] Moreover, in a retrospective cohort study conducted in Sweden during 2004-2009, 60% of 4,718 people with NP had discontinued their treatment five months after first prescription.[13] Other studies have shown that only a small proportion of people who discontinue their initial treatment switch to another medication.[14, 15]

Currently, it is not clear what predicts pharmacotherapy choice for NP, or adherence and persistence with treatment. To our knowledge, no published reviews have summarised the literature on the predictors of any of these outcomes. Identifying these predictors may inform strategies to ensure that people with NP are prescribed recommended medication and adhere to and persist with their treatment when appropriate. Therefore, we carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with NP.

2. Methods

2.1 Protocol and registration

The protocol of this systematic review and meta-analysis was prospectively registered on the PROSPERO international prospective register of systematic reviews (Registration ID: CRD42023464307). This report follows the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) checklist.[16]

2.2 Search strategy

To identify relevant studies, Embase, PubMed, Web of Science, and CINAHL Plus were searched from inception to the 10th of October 2023. The search strategy combined keywords and medical subject headings for 1) neuropathy 2) pharmacological treatments and 3) prescribing, adherence, and discontinuation. The full search terms for all the databases are reported in Table S1. The retrieved records were exported to Covidence (Veritas Health Innovation, Melbourne, Australia) and screened independently by two reviewers (MK and DS). Discrepancies were resolved by discussion with the wider review team where necessary. The reference lists of the included studies were reviewed to identify further eligible studies not identified by the search strategy.

2.3 Eligibility criteria

Studies were included if they: (1) investigated potential predictors of pain medication prescribing, adherence, or discontinuation in adults (≥18 years old) with NP; (2) were a cohort study, case-control study, cross-sectional study, randomised controlled trial (RCT), or systematic review with meta-analysis; (3) were published in full-text in English. Studies were excluded if (1) they included participants who did not have NP, where these could not be analysed separately from those who had NP; (2) they included children (<18 years old) and did not present analysis on adults separately; (3) they were a case study, case series, review without a meta-analysis, protocol, editorial, or conference abstract; (4) they were RCT that aimed to assess NP medication efficacy and the only relevant information for our review was discontinuation rates between trial medications; and/or (5) the medications of our interest could not be analysed separately from other medications. The medication categories of interest were anticonvulsants, antidepressants, opioids, non-opioid analgesics, combinations of opioids and non-opioid analgesics, local anaesthetics, N-methyl-D-aspartate (NMDA) receptor antagonists, topical pain medications, botulinum toxin A, baclofen, and clonidine. The medications that were not of interest included but were not limited to muscle relaxants, corticosteroids, sedatives, antimigraine medications. The list of medications in each category is provided in Table S2.

In our review, the word 'non-opioid analgesics' refers to non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, aspirin, and nefopam. A few eligible studies used the words 'non-opioid analgesics' and 'non-narcotic analgesics' without defining what they included. [17–20] We interpreted these as mostly consisting of NSAIDs and paracetamol as data from the other NP medications were presented separately in these studies.

Prescribing patterns of medications are often analysed retrospectively from medical claim databases which rely on identifying the relevant sample based on diagnostic codes (e.g. International Classification of Diseases [ICD] codes). However, diagnostic codes used for conditions that cause NP

often do not differentiate between painful and painless neuropathy. Thus, we included studies where the sample was identified based on diagnostic codes for neuropathy. For this reason and because of the inconsistency of terms used for NP caused by diabetes, the following terms used in included papers, were grouped under diabetic neuropathy (DN): diabetic peripheral neuropathic pain (DPNP), diabetic peripheral neuropathy (DPN), painful diabetic peripheral neuropathy (pDPN or PDPN), painful diabetic neuropathy (PDN), painful diabetic polyneuropathy, diabetic polyneuropathy. Our assumption was that relevant pain medicines were only prescribed for these conditions in these studies when the neuropathy was painful though we could not rule out the possibility of pain medicines given for other painful conditions, in the presence of a painless neuropathy.

2.4 Data extraction

Data extraction was performed independently by two reviewers (MK and DS) and discrepancies were resolved by discussion. The key extracted information included: NP diagnoses included in the study, medications that were investigated and could be included in our analysis, type of outcome, description of outcome definition/measurement, potential predictors investigated, description of the potential predictor definition/measurement, and the strength of association A full list of all extracted information is given in Table S3.

2.5 Risk of bias assessment

Risk of bias assessment was performed independently by two reviewers (MK and DS) and discrepancies were resolved by discussion. The Risk Of Bias In Non-randomized Studies - of Exposures (ROBINS-E)[21] tool was used to assess cohort studies, cross-sectional studies, and case-control studies. The "exposure" in each study was defined as the potential predictors investigated (e.g. NP diagnosis, sex, household income). The Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I)[22] tool was used to assess one non-randomised parallel assignment trial. The revised Cochrane Risk of Bias tool for randomized trials (RoB 2)[23] was used to assess three RCTs. A secondary analysis of RCTs was assessed using A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2).[24]

2.6 Synthesis of results

The included studies were grouped into non-mutually exclusive categories based on the outcomes they investigated (prescribing, adherence, and discontinuation). The studies that investigated prescribing were divided into non-mutually exclusive subgroups based on which medication categories were analysed. In each category of studies, all the potential predictors investigated were reported followed by a listing of the relevant studies per each potential predictor. For each study, we recorded whether a significant/non-significant relationship was discovered, how the potential predictor was defined, how the outcome was measured, significant effect size, and additional comments to be considered in making conclusions. If the potential predictor definition and outcome measurement were similar or could be converted to be similar, meta-analyses were conducted using RStudio (v4.3.1). For example, meta-analyses were not carried out between two studies if one measured the likelihood of discontinuation using the mean number of treatment days and the other recorded the number of medication refills. Heterogeneity was described using the I^2 test. Random-

effects models were used for all meta-analyses. The type of measure of effect estimated in each meta-analysis depended on the type of data provided in the included studies for the potential predictors. In the majority of cases, odds ratios (OR) and the associated 95% confidence intervals (CI) were calculated. In meta-analyses that were conducted using pre-calculated ORs, adjusted ORs were used rather than unadjusted ORs if possible. Forest plots were produced for each meta-analysis. The final conclusions for each potential predictor were described narratively and each potential predictor was categorised either to increase the likelihood of the investigated outcome, to not have an association with it, or to unclear/ inconsistent results.

3. Results

3.1 Study selection

Figure 1 shows a flowchart of the study selection process. Database searches identified a total of 9,453 records. Sixty studies were included in the review, and this included 6 studies identified from screening the reference lists of the eligible studies. The records excluded in full-text screening and the reasons for their exclusion are documented in Table S4.

3.2 Study characteristics

The characteristics of the included studies are summarised in Table 1. The majority of the included studies were retrospective cohort studies (37/60) conducted in the USA and Europe (50/60). There were 45 studies on prescribing, 14 on adherence, and 25 on discontinuation. Most studies included people with diabetic neuropathy (DN) along with other aetiologies (50/60) – with 23/60 studies exclusively on DN. More detailed study characteristics are given in Table S3.

3.3 Risk of bias assessment

The majority of the studies (55/60) were assessed using ROBINS-E. The results are shown in Figure S1. All of the studies assessed using ROBINS-E were deemed to have a low risk of bias in measuring exposures, post-exposure interventions, outcome measurement, and reporting of results (although the domain "post-exposure interventions" was generally irrelevant to our research question). Sixteen studies were deemed to have a high risk of bias in "confounding variables" due to adjusting for potential predictors that could affect each other. In the participant selection domain, most of the studies had "some concerns" as the exposure window of some of the investigated potential predictors would be lifelong (e.g. age or sex) and thus would precede the data collection time frame. However, these factors were unlikely to influence our interpretation of these studies. In the missing data domain, in many of the studies with a high risk of bias, no information was provided about the handling of missing data. ROBINS-I was used to assess one study[25], which was deemed to have a low risk of bias in all domains. Three RCTs were assessed using Rob 2. The results are shown in Figure S2. In these studies, the only finding of a high risk of bias was in the missing data domain for Reynolds and colleagues (2020a)[26] as there was no information about missing data. One study, a non-systematic analysis of three RCTs, [27] was assessed using AMSTAR 2 and was concluded to have a critically low (poor) overall rating. The results for each domain are shown in Table S5.

3.4 Prescribing

The division of the prescribing studies into different subcategories is shown in Figure S3. The potential predictors for being prescribed any medication, non-opioid analgesics, opioids, recommended medication, recommended medication as the first choice, and opioids as the first choice are summarised in Table 2. The potential predictors are summarised in groups based on whether they had a significant association with being prescribed the medications of the subcategory, no significant association, or inconsistent or unclear results. The results from the subcategory "What medication was prescribed as the first choice?" are only described in text as only two potential predictors were investigated. More detailed results for each subcategory are provided in Tables S6 to S10Forest plots displaying the results from the meta-analyses are shown in Figures S4 to S42.

Most of the findings about potential predictors relating to recommended medication as the first choice originate from a retrospective case-control study by Lakkad and colleagues (2023)[28]. They investigated people with NP related to breast cancer treatment and compared those who were prescribed gabapentin, pregabalin, amitriptyline, nortriptyline, desipramine, venlafaxine, duloxetine, 5% lidocaine patch, or capsaicin cream in the 180 days after NP diagnosis and those who were only prescribed opioids in the 180 days after NP diagnosis. Their results are reflected in the prescribing subcategories: recommended medication; recommended medication as the first choice; opioids; and opioids as the first choice.[28] The potential predictors of being prescribed opioids as the first choice for NP were investigated in five studies. Most of the results also for this subcategory originate from Lakkad and colleagues (2023).[28] The majority of the other results in this subcategory are provided by Patil and colleagues (2015). [29] Moreover, Hall and colleagues (2008)[17] and Hall and colleagues (2013)[18] provide results for the association of different NP diagnoses with being prescribed opioids as the first choice. The results relevant to this subcategory from Reed and colleagues (2013)[19] found that the number of people with an opioid as the first choice was smaller with a later year of DN diagnosis from 2002 to 2011. This was also investigated by Patil and colleagues (2015)[29] but they did not find a significant trend.

The results of one of the prescribing studies, Fuzier and colleagues (2018)[30], were excluded from Table 2 because this compared the proportion of people being prescribed pain medications before and after carpal tunnel syndrome (CTS) surgery which is used to relieve NP caused by CTS. No other study investigated changes in NP medication prescriptions before and after pain relieving interventions. The key findings were that being female or having high preoperative pain was associated with a greater number of people being prescribed opioids two months after surgery, and that high preoperative pain, having inpatient surgery (compared to ambulatory surgery), or having a psychiatric disorder were associated with a greater likelihood of being prescribed anticonvulsants or antidepressants two months after surgery.

In the subcategory "What medication was prescribed as the first choice?" the only potential predictors investigated were the type of NP diagnosis and the year of NP diagnosis. Gustavsson and colleagues (2013)[13] investigated the differences in being prescribed amitriptyline, clomipramine, nortriptyline, duloxetine, venlafaxine, gabapentin, and pregabalin between Swedish people with mixed pain and those with purely NP. There were no significant differences in the prescribing of these medications between people with mixed pain and those with purely NP ($p=0.08$ to 0.64). Hall and colleagues (2006)[31], Hall and colleagues (2008)[17], and Hall and colleagues (2013)[18] conducted retrospective cohort studies in the UK and they compared the five most commonly prescribed medications as the first choice in people with DN, PHN, phantom limb pain (PLP), trigeminal neuralgia (TN), and/or neuropathic back pain. These studies found that people with TN were most likely to be prescribed carbamazepine as the first choice, people with neuropathic back pain were most likely to be prescribed tramadol, people with PLP or DN were most likely to be prescribed gabapentin or amitriptyline, and people with PHN were most likely to be prescribed amitriptyline or co-codamol. Reed and colleagues (2013)[19] investigated the first-choice medications being prescribed to people with DN in the UK during 2002-2011. There was a significant decrease in the number of people being prescribed opioids and NSAIDs and a significant increase in the number of people being prescribed anticonvulsants, TCAs, and SNRIs over the 10-year period ($p<0.05$ for all results).

3.5 Adherence and discontinuation

The potential predictors that were investigated for adherence and discontinuation studies are shown in Table 3. More detailed results are provided in Table S11 to S12. Forest plots displaying the results from the meta-analyses are shown in Figure S43 to S108. Many of the studies investigating adherence quantified this as the medication possession ratio (MPR) which is calculated as the sum of days medication was dispensed in a time period divided by the number of days in that time period.[32]

Predictors with the strongest associations for adherence were: adherence to venlafaxine compared to gabapentin (OR: 2.83, 95% CI: 1.45 to 5.76, calculated[33]); adherence to duloxetine compared to pregabalin (meta-analysis result OR: 2.41, 95% CI: 1.01 to 5.80); any pregabalin dose titration within 45 days compared to no titration (OR: 2.59, 95% CI: 2.22 to 3.02)[34]; any mirogabalin dose titration during days 16-30 compared to no dose titration (OR: 2.57, 95% CI: 1.29 to 5.13)[35]; having a medicine reminder (RR: 2.38, 95% CI: 1.58 to 3.61)[36]; being >55 years old compared to being 18-44 years old (OR: 2.12, 95% CI: 1.30 to 3.46)[37]; being 55-64 years old compared to 18-44 years old (OR: 2.10, 95% CI: 1.30 to 3.37)[38]; adherence to >60 mg/day duloxetine compared to 30 mg/day duloxetine (Mean MPR: 65% vs 35%, $p<0.05$)[38]; and pregabalin adherence in people with DN compared to people with PHN (mean proportion of days covered (PDC): 63% vs 48%, $p<0.05$)[39].

In individual studies, geographical differences in NP pharmacotherapy adherence have only been compared between different regions within the USA. Based on our meta-analyses using data from Yeh and colleagues (2021)[34], Reynolds and colleagues (2020a)[26], and Chen and colleagues (2010b)[38], people living in North Central USA and Middle Atlantic USA were found to have better adherence compared to people living South USA. The results between studies from other geographical regions suggest that NP pharmacotherapy adherence may be better in Japan and Europe than in the USA. A Japanese study that investigated mirogabalin dose titration found that the number of people with ≥80% MPR was 97.6% among those with dose titration and 95.9% among those without dose titration (OR: 1.75, 95% CI: 1.21 to 2.54), which demonstrated excellent adherence in Japan.[35] In Spain, two studies found that brand-name medications had higher mean MPR than generic medications (gabapentin: 86.5% vs 81.3%, $p<0.001$; pregabalin: 83.5% vs 78.4%, $p<0.001$).[20, 40] Similarly, a Greek study found that the proportion of people taking >75% of their medication was 82.9% for gabapentin and 93.5% for selective serotonin reuptake inhibitors (SSRIs) ($p<0.05$). Thus, European studies demonstrated a good level of adherence, whereas this was much lower in the USA (where all the other adherence studies were conducted). The study with the largest sample from the USA (N=57,495) found that during 2004-2016 the mean MPR of gabapentinoids was around 45%-50% and mean MPR of SNRIs was around 55%-60%.[11]

The factors with the strongest evidence of association with discontinuation were: having moderate adverse effects (OR: 8.64, 95% CI: 4.42 to 16.89); having severe adverse effects (OR: 5.37, 95% CI: 2.01 to 14.00); or resultant nausea, somnolence, headache, or dizziness (ORs: 3.17-4.93, large CIs).[27] These results were based on an analysis of three RCTs investigating the use of gabapentin in people with postherpetic neuralgia. In contrast, having a clinically significant reduction in pain (≥ 50% from baseline) only had a weak association (OR: 1.2; 95% CI: 1.0 to 1.4) on treatment persistence in a retrospective cohort study investigating pregabalin.[40] Moreover, Wang and colleagues (2020)[41] found that people with DN had a much higher mean number of days on therapy compared to people with postherpetic neuralgia (222 days vs 89 days, OR: 4.24, 95% CI: 4.00 to 4.51). In our meta-analysis including four other studies, the mean difference in treatment duration between people with DN and people with PHN was 51 days (95% CI: 4 to -98) days.

The differences in therapy duration between medications were investigated by ten studies. Gore and colleagues (2007a)[42] (N= 30,999) and Hall and colleagues (2008)[17] (N=5,101) compared the most medications. Gore and colleagues (2007a)[42] recorded treatment durations in mean number of days

on medication while Hall and colleagues (2008)[17] recorded the number of people with stable therapy after one year (15-30%). The longest therapy duration measured in mean number of days on medication was 122 days in the group of people with SSRIs. The results from both of these studies show that people were more likely to discontinue TCAs compared to other antidepressants. Heatmaps showing the pairwise meta-analyses between all the investigated medications in these studies are shown in Figure 2-3.

Based on the mean number of treatment days reported by Gore and colleagues (2007a)[42] and the pairwise meta-analysis heatmap, the medications they investigated were ranked in order of decreasing adherence: SSRIs (126 days); 2nd generation antidepressants (includes SSRIs and SNRIs [122 days]); antiepileptics (113 days); SNRIs (103 days); gabapentin (100 days); long-acting opioids (100 days); carbamazepine (93 days); COX 1 inhibitors (91 days); all TCAs (91 days); NSAIDs (90 days); amitriptyline (87 days); opioids (80 days); COX 2 inhibitors (79 days); and short-acting opioids (79 days). There was no significant difference in adherence between SSRIs and 2nd generation antidepressants, but SSRIs were taken for a significantly longer time than antiepileptics, which in turn were used for a significantly longer time than SNRIs. There were no significant differences in adherence between SNRIs, gabapentin, long-acting opioids, and carbamazepine. COX 1 inhibitors, TCAs, and NSAIDs did not show a statistically significant difference compared to carbamazepine or long-acting opioids, but they were all taken for a significantly shorter time than gabapentinoids. Amitriptyline was taken for as long as all TCAs or NSAIDs but taken used for a significantly shorter time than COX 1 inhibitors. Opioids, COX 2 inhibitors, and short-acting opioids were taken for similar durations, but for a shorter time than amitriptyline.

Other studies investigating differences in discontinuation between medications showed that people who were prescribed duloxetine were less likely to continue compared to people who were prescribed pregabalin or gabapentin,[15, 43] whilst there did not seem to be difference between pregabalin or gabapentin.[44–46]

4. Discussion

Our systematic review and meta-analysis aimed to understand the predictors of NP pharmacotherapy prescribing, adherence, and discontinuation. In the 60 included studies, prescribing was analysed in 45 studies, adherence in 14 studies, and discontinuation in 25 studies. In each category, the studies were heterogeneous in terms of which potential predictors were investigated, how the potential predictors were defined, how the outcomes were measured, and the precise list of medications that were studied. Having a diagnosis of NP, diabetes, diabetic neuropathy and/or mental health disorder were associated with being prescribed recommended medication for NP. Younger age in people over 65 years old, male gender, and/or having neuropathic back pain were associated with being prescribed non-opioid analgesics. Having anxiety, depression, diabetic neuropathy and/or a mental health disorder were associated with being prescribed opioids.

Studies that investigated potential predictors of NP medication prescribing often did not report their analysis such that the participants were exclusively prescribed the medication that was analysed and no other pain medications. For example, if potential predictors of being prescribed opioids were analysed, it was not reported whether these people received other pain medications. This is an important consideration when interpreting the results of prescribing subcategories: recommended treatment; opioids; and non-opioid analgesics. Thus, the studies investigating first choice prescriptions may be more informative. Currently, most of the results about the potential predictors of recommended medications as the first choice originate from Lakkad and colleagues (2023).[28] Their results showed that having white ethnicity, mental health disorders, diabetes, dementia, hemiplegia, and/or previous use of antipsychotics, benzodiazepines, or other central nervous system depressants were associated with being prescribed recommended medication. Other studies investigating first choice medications found that people with DN were more likely to be prescribed a recommended NP medication compared to people with PHN or phantom limb pain, while people with neuropathic back pain were the least likely to be prescribed a recommended NP medication.[17, 18, 47] Studies outside the remit of our review on nociceptive pain have also found that white ethnicity and having mental health disorders were associated with being prescribed pain treatment.[48, 49]

Moreover, the included studies investigating NP pharmacotherapy adherence also found that white ethnicity and DN were associated with better adherence. Medication-related characteristics such as having dose titration, brand-name medication, and lower cost of medication were associated with better adherence. Having brand-name medication was also associated with a lower likelihood of discontinuing NP pharmacotherapy. Adherence to SNRIs was found to be better than adherence to TCAs or gabapentinoids. Similarly, treatment persistence with SNRIs was better than treatment persistence with TCAs or gabapentinoids.

Adherence predictors with the strongest associations were being prescribed venlafaxine compared to gabapentin, being prescribed duloxetine compared to pregabalin, dose titration, having a medicine reminder, being 55-64 years old (compared to 18-54 years old), and having diabetic neuropathy compared to postherpetic neuralgia. These results suggest that the best ways to improve NP pharmacotherapy adherence are to prescribe SNRIs instead of gabapentinoids or TCAs if appropriate, use dose titration, and a medicine reminder.

Comparing the results between adherence studies, it could be argued that adherence varies between countries – potentially even more than based on the potential predictors that were investigated. In Japanese and European studies, adherence was generally around or above 80% and the investigated predictors were only associated with small differences in adherence. In contrast, in studies conducted in the USA, adherence tended to be much less than 80% regardless of the

potential predictors that were investigated. Taking the small number of studies conducted outside of the USA and the considerable variation in the level of adherence between the studies conducted in the USA, it is possible that these trends could merely reflect between-study differences rather than regional differences. However, the results from studies investigating adherence with other medications support the geographical trends we identified. For example, a meta-analysis investigating heart failure medications found that adherence was higher in Europe and Asia than in North America.[50] Hence, it would be worthwhile documenting regional differences in future NP pharmacotherapy adherence studies and exploring the potential underlying factors. It is noteworthy that a study comparing adherence to a variety of medications between European countries found that the between-country differences could not be explained by socio-demographic or socio-economic variables.[51]

Only two eligible studies investigated the clinical effectiveness of NP medications and their adverse effects as potential predictors of discontinuation. It is interesting that our review did not identify any other studies specifically investigating adverse events or clinical effectiveness as potential predictors of discontinuation although they are key aspects of successful drug development. Perhaps the most important observation from the discontinuation studies is that most people with NP discontinued their treatment within half a year regardless of the presence of predictors that were found to be associated with longer treatment duration. None of the included studies investigated potential predictors for the minority that continued treatment for a long time. Moreover, Yang and colleagues (2015)[15] and Dworkin and colleagues (2012)[14] found that only a small proportion of people who discontinued their initial treatment switched to another one. It is possible that NP pharmacotherapy is discontinued due to the resolution of pain, for example in people with PHN,[52] but this is unlikely to be the case for people with diabetic neuropathic pain, whose pain is highly likely to persist and exacerbate.[53]

4.1 Limitations

Due to the heterogeneity of the studies, the conclusions about each potential predictor were based on a small number of studies. In addition, the significantly associated predictors tended to have weak associations or large confidence intervals (See Table S6 to S12 and Figures S4 to S108). It should be noted that although the diagnosis of interest in this study was NP, most of the included studies were not able to differentiate between painful and painless neuropathy based on the information provided in the databases they investigated. Studies often defined their sample using International Classification of Diseases (ICD) 9 or 10 codes and pain medication claims, but it was only in ICD-11 that a specific code for neuropathic pain was developed.[54] The lack of information about the presence and level of pain in the included studies creates a major limitation in identifying NP pharmacotherapy predictors in those with the most need for treatment. Future studies could be improved by seeking additional data sources that allow classifying the sample into mild, moderate, and severe pain categories. Another limitation in our work is that our analysis focused on finding an overall trend for each potential predictor disregarding explanations for within-predictor inconsistencies. It is possible that our findings are context-specific (e.g. specific NP diagnosis or medication) and more detailed conclusions may arise later with more studies. Analysing within-predictor trends was not considered worthwhile in this review due to the small number of studies per each potential predictor.

We made a pragmatic decision to exclude RCTs that are primarily designed to assess the efficacy of NP medications from our review. The medications given in these trials could be compared as the

potential predictors for discontinuation. However, as our review aims to summarise all the potential predictors for NP medication prescribing, adherence, and discontinuation; including these trials in our review would focus disproportionately on one type of predictor (>200 RCTs)[7] compared to all the predictors. We do not believe that the inclusion of this group of studies would materially change the conclusions derived from our review.

4.2 Conclusion

The current literature about NP pharmacotherapy predictors is heterogeneous in design but provides some valuable conclusions about the predictors that have been investigated. The results show that there is a need to focus on improving treatment allocation for non-white populations and people with NP caused by aetiologies other than diabetes. In addition, adherence and persistence with NP medications could be improved by prioritising prescribing of SNRIs if appropriate. These, and the other factors we identified should be considered in the development of future NP pharmacotherapy guidelines. Our review observed that most people with NP discontinued their treatment within half a year but the predictors for this are not clear.

Details of authors' contributions

Study conception and design: MK, LC, BS, HH

Acquisition of data: MK, DS

Analysis and interpretation of data: MK, DS, BS, HH, LC

Drafting of final manuscript: MK

Revision and critical appraisal of the manuscript: MK, BS, HH, DS, LC

Final approval of the submitted manuscript: MK, BS, HH, DS, LC

Acknowledgments

We would like to acknowledge Mr Scott McGregor (University of Dundee Library Academic and Cultural Services) for his assistance in developing the search strategy.

Declaration of interest

This systematic review was conducted as part of MK's PhD studentship funded by The National Institute of Academic Anaesthesia [British Journal of Anaesthesia / Royal College of Anaesthetists, WKR0-2022-0028]. DS is a fellow on the Multimorbidity Doctoral Training Programme for Health Professionals, which is supported by the Wellcome Trust [223499/Z/21/Z]. LC receives research support funding, on behalf of her institution, from the Advanced Pain Discovery Platform (funded by UK Research and Innovation, Versus Arthritis, Eli Lilly), the Scottish Government (Chief Scientist Office), The Wellcome Trust, and the National Institute of Academic Anaesthesia. She is Vice Chair of Scottish Intercollegiate Guidelines Network (SIGN) Council and is currently chairing the SIGN Guideline Development Group for Management of Chronic Pain. BHS receives research support funding, on behalf of his institution, from UK Research and Innovation (Medical Research Council), Versus Arthritis, the Scottish Government (Chief Scientist Office), Eli Lilly, The Wellcome Trust, and the National Institute of Academic Anaesthesia. HLH has received funding to support research from The National Institute of Academic Anaesthesia [British Journal of Anaesthesia / Royal College of Anaesthetists].

Funding

This systematic review was conducted as part of MK's PhD studentship funded by The National Institute of Academic Anaesthesia [British Journal of Anaesthesia / Royal College of Anaesthetists, WKR0-2022-0028].

References

1. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain* 2005; **114**: 29–36

2. Treede R-D, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. *Neurology* 2008; **70**: 1630–5

3. Baskozos G, Hébert HL, Pascal MM, et al. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. *Pain Rep* 2023; **8**: e1066

4. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: A systematic review of epidemiological studies. *PAIN* 2014; **155**: 654

5. Langley PC, Van Litsenburg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in Western Europe. *J Med Econ* 2013; **16**: 85–95

6. Torrance N, Lawson KD, Afolabi E, et al. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: Does the choice between the EQ-5D and SF-6D matter? *Pain* 2014; **155**: 1996–2004

7. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015; **14**: 162–73

8. Mendlik MT, Uritsky TJ. Treatment of Neuropathic Pain. *Curr Treat Options Neurol* 2015; **17**: 50

9. Vo T, Rice ASC, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: How do we explain continued widespread use? *PAIN®* 2009; **143**: 169–71

10. Callaghan BC, Reynolds E, Banerjee M, Kerber KA, Skolarus LE, Burke JF. Longitudinal pattern of pain medication utilization in peripheral neuropathy patients. *Pain* 2019; **160**: 592–9

11. Reynolds EL, Burke JF, Banerjee M, et al. Association of out-of-pocket costs on adherence to common neurologic medications. *Neurology* [Internet] 2020 [cited 2024 Apr 7]; **94** Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000009039

12. Burnier M. Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence. *Front Pharmacol* [Internet] Frontiers; 2019 [cited 2024 Oct 6]; **9** Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01540/full

13. Gustavsson A, Bjorkman J, Ljungcrantz C, et al. Pharmacological Treatment Patterns in Neuropathic Pain—Lessons from Swedish Administrative Registries. *Pain Med* 2013; **14**: 1072–80

14. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations? *Pain* 2012; **153**: 869–75

15. Yang M, Qian C, Liu Y. Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States. *Pain Med* 2015; **16**: 2075–83

16. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* British Medical Journal Publishing Group; 2021; **372**: n160

17. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: A descriptive study, 2002–2005. *BMC Fam Pract* 2008; **9**: 26

18. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. *BMC Fam Pract* 2013; **14**: 28

19. Reed C, Hong J, Novick D, Lenox-Smith A, Happich M. Incidence of diabetic peripheral neuropathic pain in primary care – a retrospective cohort study using the United Kingdom General Practice Research Database. *Pragmatic Obs Res* Dove Press; 2013; **4**: 27–37

20. Sicras-Mainar A, Rejas J, Navarro-Artieda R. Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain. *Clin Outcomes Res* 2015; 299

21. Higgins JPT, Morgan RL, Rooney AA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). *Environ Int* 2024; **186**: 108602

22. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *The BMJ* 2016; **355**: i4919

23. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* British Medical Journal Publishing Group; 2019; **366**: l4898

24. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* British Medical Journal Publishing Group; 2017; **358**: j4008

25. Knoerl R, Mazzola E, Hong F, et al. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study. *BMC Cancer* 2021; **21**: 236

26. Reynolds EL, Burke JF, Banerjee M, Callaghan BC. Randomized controlled trial of a clinical decision support system for painful polyneuropathy. *Muscle Nerve* 2020; **61**: 640–4

27. Shaparin N, Slattum PW, Bucior I, Nalamachu S. Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin. *Clin J Pain* 2015; **31**: 983–91

28. Lakkad M, Martin B, Li C, Harrington S, Dayer L, Painter JT. Factors Associated With Guideline-Concordant Pharmacological Treatment for Neuropathic Pain Among Breast Cancer Survivors. *Clin Breast Cancer* 2023; **23**: 598–619

29. Patil PR, Wolfe J, Said Q, Thomas J, Martin BC. Opioid Use in the Management of Diabetic Peripheral Neuropathy (DPN) in a Large Commercially Insured Population. *Clin J Pain* 2015; **31**: 414–24

30. Fuzier R, Serres I, Bourrel R, Palmaro A, Lapeyre-Mestre M. Analgesic Drug Prescription After Carpal Tunnel Surgery: A Pharmacoepidemiological Study Investigating Postoperative Pain. *Reg Anesth Pain Med* 2018; **43**: 19–24

31. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: The UK primary care perspective. *Pain* 2006; **122**: 156–62

32. Shah KK, Touchette DR, Marrs JC. Research and scholarly methods: Measuring medication adherence. *JACCP J Am Coll Clin Pharm* 2023; **6**: 416–26

33. Gharibian D, Polzin JK, Rho JP. Compliance and Persistence of Antidepressants Versus Anticonvulsants in Patients With Neuropathic Pain During the First Year of Therapy. *Clin J Pain* 2013; **29**: 377–81

34. Yeh Y-C, Cappelleri JC, Marston XL, Shelbaya A. Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database study. Mallhi TH, editor. *PLOS ONE* 2021; **16**: e0242467

35. Kato K, Kodama S, Shiosakai K, Kimura T. Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study. *Expert Opin Pharmacother* 2023; **24**: 267–82

36. Sutema IAMP, Jaya MKA, Bakta IM. Medicine reminder to improve treatment compliance on geriatric patients with diabetic neuropathy at Sanglah Central Hospital, Bali-Indonesia. *Bali Med J* 2018; **7**: 516

37. Wu N, Chen S, Boulanger L, Fraser K, Bledsoe SL, Zhao Y. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. *J Med Econ* 2009; **12**: 192–202

38. Chen S-Y, Wu N, Boulanger L, Fraser KA, Zhao Y. The Relationship Between Average Daily Dose, Medication Adherence, and Health-Care Costs among Diabetic Peripheral Neuropathic Pain Patients Initiated on Duloxetine Therapy: Duloxetine Average Daily Dose, Adherence and Costs. *Pain Pract* 2010; **10**: 530–9

39. Sanchez RJ, Mardekian J, Clair AG, Cappelleri JC. Therapeutic and Subtherapeutic Dosing of Pregabalin: Medication Adherence, Healthcare Resource Utilization, and Costs. *Peripher Neuropathy*

40. Sicras-Mainar A, Rejas-Gutiérrez J, Pérez-Paramo M, Sánchez-Alvarez L, Navarro-Artieda R, Darbà J. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin. *Expert Rev Pharmacoecon Outcomes Res* 2019; **19**: 45–57

41. Wang Y-F, Chen Y-T, Tsai C-W, et al. Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study. *J Headache Pain* 2020; **21**: 54

42. Gore M, Dukes E, Rowbotham DJ, Tai K, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. *Eur J Pain* 2007; **11**: 652–64

43. Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. *Curr Med Res Opin* 2011; **27**: 785–92

44. Banks C, A. Bowman L, Merrey J, Waldfogel JM. Characterization of Outpatient Gabapentinoid Prescribing for Pain. *J Pain Palliat Care Pharmacother* 2023; **37**: 143–7

45. Dragic L, Webb T, Chandler M, et al. Comparing Effectiveness of Gabapentin and Pregabalin in Treatment of Neuropathic Pain: A Retrospective Cohort of Palliative Care Outpatients. *J Pain Palliat Care Pharmacother* 2020; **34**: 192–6

46. Johnson P, Becker L, Halpern R, Sweeney M. Real-World Treatment of Post-herpetic Neuralgia with Gabapentin or Pregabalin. *Clin Drug Investig* 2013; **33**: 35–44

47. Margolis J, Princic N, Smith D, et al. Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims. *J Pain Res* 2017; **Volume 10**: 327–39

48. Brennan PL, Greenbaum MA, Lemke S, Schutte KK. Mental health disorder, pain, and pain treatment among long-term care residents: Evidence from the Minimum Data Set 3.0. *Aging Ment Health* Routledge; 2019; **23**: 1146–55

49. Morales ME, Yong RJ. Racial and Ethnic Disparities in the Treatment of Chronic Pain. *Pain Med Malden Mass* 2021; **22**: 75–90

50. Ruppar TM, Delgado JM, Temple J. Medication adherence interventions for heart failure patients: A meta-analysis. *Eur J Cardiovasc Nurs* 2015; **14**: 395–404

51. Larsen J, Stovring H, Kragstrup J, Hansen DG. Can differences in medical drug compliance between European countries be explained by social factors: analyses based on data from the European Social Survey, round 2. *BMC Public Health* 2009; **9**: 145

52. Reda H, Greene K, Rice FL, Rowbotham MC, Petersen KL. Natural history of herpes zoster: Late follow-up of 3.9 years (n = 43) and 7.7 years (n = 10). *PAIN®* 2013; **154**: 2227–33

53. Boulton AJM, Armstrong WD, Scarpello JHB, Ward JD. The natural history of painful diabetic neuropathy—a 4-year study. *Postgrad Med J* 1983; **59**: 556–9

54. Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. *Pain* 2019; **160**: 53–9

55. Anderson SG, Malipatil NS, Roberts H, Dunn G, Heald AH. Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in type 1 diabetes. *Prim Care Diabetes* 2014; **8**: 65–9

56. Anderson SG, Narayanan RP, Dunn G, Heald AH. Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in people with type 2 diabetes. 2016; **20**

57. Berger A, Dukes E, McCarberg B, Liss M, Oster G. Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia. *Clin Ther* 2003; **25**: 2809–21

58. Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. *Curr Med Res Opin* 2009; **25**: 1763–73

59. Butler S, Eek D, Ring L, Gordon A, Karlsten R. The utility/futility of medications for neuropathic pain – an observational study. *Scand J Pain* De Gruyter; 2019; **19**: 327–35

60. Chahine B, Al Souheil F. Dispensing patterns of drugs used for neuropathic pain and adherence to NeuPSIG guideline: an observational study. *Egypt J Neurol Psychiatry Neurosurg* 2021; **57**: 142

61. Chen S, Wu N, Fraser K, Boulanger L, Zhao Y. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments. *Curr Med Res Opin* 2010; **26**: 2507–16

62. Chen S, Wu N, Boulanger L, Fraser K, Zhao Z, Zhao Y. Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study. *J Med Econ* 2011; **14**: 411–20

63. Dieleman JP, Kerklaan J, Huygen FJPM, Bouma PAD, Sturkenboom MCJM. Incidence rates and treatment of neuropathic pain conditions in the general population . *Pain* 2008; **137**: 681–8

64. Giannopoulos S, Kosmidou M, Sarmas I, et al. Patient Compliance With SSRIs and Gabapentin in Painful Diabetic Neuropathy. *Clin J Pain* 2007; **23**: 267–9

65. Gore M, Sadosky A, Tai K-S, Stacey B. A Retrospective Evaluation of the Use of Gabapentin and Pregabalin in Patients with Postherpetic Neuralgia in Usual-Care Settings. *Clin Ther* 2007; **29**: 1655–70

66. Gore M, Zlateva G, Tai K, Chandran AB, Leslie D. Retrospective Evaluation of Clinical Characteristics, Pharmacotherapy and Healthcare Resource Use among Patients Prescribed Pregabalin or Duloxetine for Diabetic Peripheral Neuropathy in Usual Care. *Pain Pract* 2011; **11**: 167–79

67. Gore M, Tai K, Zlateva G, Bala Chandran A, Leslie D. Clinical Characteristics, Pharmacotherapy, and Healthcare Resource Use among Patients with Diabetic Neuropathy Newly Prescribed Pregabalin or Gabapentin. *Pain Pract* 2011; **11**: 528–39

68. Goswami S, Ramachandran S, Sharma M, Barnard M. Gabapentin and Opioids Utilization in Patients With Diabetic Neuropathy Enrolled in Medicare (2012–2016): A Cohort Study. *J Pharm Pract* 2023; **36**: 1085–94

69. Jacob L, Kaiser M, Kostev K. Incidence of antiepileptic drug therapy and factors associated with their prescribing in outpatients with diabetic polyneuropathy. *Prim Care Diabetes* 2021; **15**: 535–40

70. Johnston SS, Udall M, Alvir J, McMorrow D, Fowler R, Mullins D. Characteristics, Treatment, and Health Care Expenditures of Medicare Supplemental-Insured Patients with Painful Diabetic Peripheral Neuropathy, Post-Herpetic Neuralgia, or Fibromyalgia. *Pain Med* 2014; **15**: 562–76

71. Koopman JSHA, Huygen FrankJ, Dieleman JP, De Mos M, Sturkenboom MCJM. Pharmacological Treatment of Neuropathic Facial Pain in the Dutch General Population. *J Pain* 2010; **11**: 264–72

72. Kuo K-L, Brixner D, Lipman AG, Goodman M, Hung M, Oderda GM. Single- Versus Multiple-Drug Pharmacotherapy in the Management of Diabetic Painful Neuropathy. *J Pain Palliat Care Pharmacother* 2016; **30**: 184–94

73. Martinez V, Attal N, Vanzo B, et al. Adherence of French GPs to Chronic Neuropathic Pain Clinical Guidelines: Results of a Cross-Sectional, Randomized, "e" Case-Vignette Survey. Manchikanti L, editor. *PLoS ONE* 2014; **9**: e93855

74. Mbrah AK, Nunes AP, Hume AL, et al. Prevalence and treatment of neuropathic pain diagnoses among U.S. nursing home residents. *Pain* 2022; **163**: 1370–7

75. Oladapo AO, Barner JC, Rascati KL, Strassels SA. A Retrospective Database Analysis of Neuropathic Pain and Oral Antidiabetic Medication Use and Adherence Among Texas Adults With Type 2 Diabetes Enrolled in Medicaid. *Clin Ther* 2012; **34**: 605–13

76. Pérez C, Navarro A, Saldaña MT, Masramón X, Pérez M, Rejas J. Clinical and Resource Utilization Patterns in Patients with Refractory Neuropathic Pain Prescribed Pregabalin for the First Time in Routine Medical Practice in Primary Care Settings in Spain. *Pain Med* 2013; **14**: 1954–63

77. Pillay P, Wadley AL, Cherry CL, Karstaedt AS, Kamerman PR. Pharmacological treatment of painful HIV-associated sensory neuropathy. *S Afr Med J* 2015; **105**: 769–72

78. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. *Diabetes Metab Syndr Obes Targets Ther* 2013; 79

79. Toth C, Brady S, Hatfield M. The importance of catastrophizing for successful pharmacological treatment of peripheral neuropathic pain. *J Pain Res* 2014; 327

80. Udall M, Kudel I, Cappelleri JC, et al. Epidemiology of physician-diagnosed neuropathic pain in Brazil. *J Pain Res* 2019; **Volume 12**: 243–53

81. Winterbottom LM, Fong AM, Benkstein KL, Liang B, Snodgrass LS, Parks-Huitron H. Impact of a Clinical Pharmacy Consult Service on Guideline Adherence and Management of Gabapentin for Neuropathic Pain. *J Manag Care Pharm* 2006; **12**: 61–9

82. Wu N, Chen S, Hallett LA, et al. Opioid Utilization and Health-Care Costs among Patients with Diabetic Peripheral Neuropathic Pain Treated with Duloxetine vs. Other Therapies. *Pain Pract* 2011; **11**: 48–56

83. Zhao Y, Liu J, Zhao Y, Thethi T, Fonseca V, Shi L. Predictors of Duloxetine versus Other Treatments among Veterans with Diabetic Peripheral Neuropathic Pain: A Retrospective Study. *Pain Pract* 2012; **12**: 366–73

Figure legends

Figure 1. Flowchart of the study selection process. Out of 6429 records, 60 studies were included in our review.

Figure 2. Discontinuation between different medications based on Gore and colleagues (2007a) data. Heatmap of mean differences in mean treatment days between medications. Mean differences written in bold text were statistically significant. The figure is easiest read from x-axis to y-axis. For example, SNRIs had 12 days longer treatment duration than TCAs.

Figure 3. Discontinuation between different medications based on Hall and colleagues (2008) data. Heatmap of odds ratios for stable treatment at one year between medications. Odds ratios written in bold text were statistically significant. The figure is easiest read from x-axis to y-axis. For example, the odds ratio for having stable treatment at one year using 'other antidepressants' compared to TCAs was 1.56. Local anaesthetics, 'other antidepressants', and rubefacients/other topical antirheumatics had small sample sizes (N=22, N=131, N=228 respectively) while the sample sizes in other groups were 1029 to 1463.

Tables

*Table 1. Characteristics of the included studies. *Median age instead of mean age. F: female, NR: not reported, NP: neuropathic pain, DN: diabetic neuropathy, PHN: postherpetic neuralgia, CTS: carpal tunnel syndrome, TN: trigeminal neuralgia, PLP: phantom limb pain, CIPN: chemotherapy-induced peripheral neuropathic pain, PSN: post-surgical neuropathic pain, PTN: post-traumatic neuropathic pain, HIV-SN: human immunodeficiency virus-associated sensory neuropathy, SCI: spinal cord injury, COX: cyclooxygenase, TCA: tricyclic antidepressant, SNRI: serotonin and norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor.*

Study	Outcomes	Study design	Country & data time frame	Sample characteristics	NP diagnoses	Key findings
Anderson and colleagues (2014)[55]	Prescribing	Cross-sectional	UK NR	Size: 1,621 F: 42.2% Age: 47.6	DN	Factors associated with being prescribed pharmacological treatment included: living in a region with higher deprivation, female gender, higher body mass index, older age.
Anderson and colleagues (2015)[56]	Prescribing	Cross-sectional	UK NR	Size: 3,226 F: NR Age: NR	DN	Factors associated with being prescribed pharmacological treatment included: living in a region with higher deprivation, female gender, higher body mass index, older age.
Banks and colleagues (2023)[44]	Discontinuation	Retrospective cohort	USA 2017-2021	Size: 1,221 F: 58.6% Age: 58*	DN	No significant difference in duration of therapy between people with pregabalin compared to people with gabapentin.
Berger and colleagues (2003)[57]	Prescribing	Retrospective cohort	USA 1999-2002	Size: 45 F: 73.3% Age: 73	PHN	Having several gabapentin prescriptions was associated with a higher likelihood of opioid use.
Boulanger and colleagues (2009)[58]	Prescribing	Retrospective cohort	USA 2004-2006	Size: 27,779 F: 51.5% Age: 64.8	DN	People who had anxiety and/or depression were more likely to be prescribed any pain medication, antidepressants, anticonvulsants, or opioids.
Butler and colleagues (2018)[59]	Prescribing	Prospective cohort	Canada 2010-2013	Size: 210 F: 42.2% Age: 55.2	DN PTN	People with PTN were more likely to use opioids, antiepileptics, TCAs, and other antidepressants, compared to people with DN. People with DN were more likely to use COX inhibitors.

Callaghan and colleagues (2019)[10]	Prescribing	Retrospective cohort	USA 2001-2014	Size: 14,426 F: 47.6% Age: 43.1	Peripheral NP	No factors were associated with both a high probability of opioid prescription initiation and chronic prescription, *and* a low probability of guideline-recommended medication prescriptions. Factors associated with a higher probability of being prescribed any pain medication included female gender, younger age, white ethnicity, having diabetes, anxiety, or depression.
Chahine and Al Souheil (2021)[60]	Prescribing	Cross-sectional	Lebanon 2019	Size: 360 F: 55% Age: 50.2	Several	Factors associated with being prescribed/dispensed SNRIs, TCAs, or gabapentinoids included: younger age, low alcohol intake, and DN diagnosis. Factors associated with being prescribed opioids included smoking and high alcohol intake.
Chen and colleagues (2010a)[61]	Prescribing Discontinuation	Retrospective cohort	USA 2004-2006	Size: 234 F: 57.3% Age: 55	DN	People who were prescribed duloxetine were less likely to use opioids compared to those who were prescribed other recommended NP medications.
Chen and colleagues (2010b)[38]	Adherence Discontinuation	Retrospective cohort	USA 2003-2007	Size: 1,351 F: 59% Age: 54.7	DN	30 mg/day duloxetine was associated with lower adherence and shorter therapy duration compared to 60 mg/day duloxetine.
Chen and colleagues (2011)[62]	Prescribing	Retrospective case-control	USA 2004-2007	Size: 11,060 F: 54% Age: 55.4	DN	People who had lower back pain or had previously used duloxetine or pregabalin were more likely to initiate duloxetine compared to other medications.
Dieleman and colleagues (2008)[63]	Prescribing	Retrospective cohort	Netherlands 1996-2003	Size: NR F: NR Age: NR	Mononeuropathy CTS DN PHN Facial NP	People with CTS were less likely to be prescribed any pain medication compared to those with other NP diagnosis. People with PHN were more likely to be prescribed more than one medication compared to those with other NP diagnosis. Different NP diagnoses affected the probability of being prescribed specific pain medications.
Dragic and colleagues (2020)[45]	Discontinuation	Retrospective cohort	USA 2014-2017	Size: 252 F: 51.2% Age: 52.9	NR	A higher proportion of people prescribed gabapentin reported discontinuations due to adverse events compared to people prescribed pregabalin.
Dworkin and colleagues (2012)[14]	Discontinuation	Retrospective case-control	USA 2005-2006	Size: 808 F: NR Age: NR	PHN	People with PHN had longer therapy duration with first-line and third-line medications compared to second-line medications.

Fuzier and colleagues (2018)[30]	Discontinuation	Retrospective cohort	France 2009-2011	Size: 3,665 F: 66% Age: 58	CTS	Females and those with high preoperative pain were more likely to increase/keep opioid prescriptions after CTS surgery.
Gharibian and colleagues (2013)[33]	Adherence Discontinuation	Retrospective cohort	USA 2007-2008	Size: 1,817 F: 57.5% Age: 59.4	NR	No difference in adherence or treatment persistence was observed between people who were prescribed antidepressants and people who were prescribed anticonvulsants. People prescribed venlafaxine had higher adherence than people prescribed gabapentin or TCAs.
Giannopoulos and colleagues (2007)[64]	Adherence	RCT	Greece NR	Size: 101 F: NR Age: 57	DN	People with DN had better adherence with SSRIs than gabapentin in a 6-month-long trial.
Gore and colleagues (2007a)[42]	Prescribing Discontinuation	Retrospective cohort	UK 2001	Size: 30,999 F: 59.8% Age: 54.9	Peripheral NP	People with pure NP were more likely to be prescribed TCAs, second-generation antidepressants, and antiepileptics, while people with mixed NP were more likely to be prescribed NSAIDs and opioids. People with SSRIs or SNRIs had longer therapy duration compared to people with other pain medications.
Gore and colleagues (2007b)[65]	Prescribing	Retrospective case-control	USA 2005-2006	Size: 251 F: 59% Age: 54.6	PHN	People who were younger, had depression, or other NP diagnoses were more likely to be prescribed pregabalin than gabapentin. Those who were prescribed pregabalin had less opioid use compared to those who were prescribed gabapentin.
Gore and colleagues (2011a)[66]	Prescribing	Retrospective cohort	USA 2004-2006	Size: 1,426 F: 60.3% Age: 55.9	DN	After being prescribed pregabalin, people had fewer anticonvulsant and opioid prescriptions and more SNRI prescriptions. After being prescribed duloxetine, people had fewer SNRI and opioid prescriptions and more anticonvulsant prescriptions.
Gore and colleagues (2011b)[67]	Prescribing	Retrospective cohort	USA 2004-2006	Size: 2,356 F: 53.4% Age: 56.7	DN	People who were prescribed pregabalin as well as those who were prescribed gabapentin had higher proportions of people with most pain medications after the prescription compared to before the prescription.

Goswami and colleagues (2023)[68]	Prescribing	Retrospective case-control	USA 2012-2016	Size: 7,017 F: 57.1% Age: NR	DN	Factors associated with being prescribed concomitant gabapentin and opioids included: female gender, younger age, having anxiety, and having other comorbidities.
Gustavsson and colleagues (2013)[13]	Prescribing Discontinuation	Retrospective cohort	Sweden 2004-2009	Size: 4,718 F: 60.6% Age: 56.2	Pure NP Mixed pain	Over 3 years, people with mixed pain had a faster rate of pain medication discontinuation compared to people with pure NP.
Hall and colleagues (2006)[31]	Prescribing Discontinuation	Retrospective cohort	UK 1992-2002	Size: 25,824 F: 62% Age: NR	PHN TN PLP DN	The most common first-line treatment in people with DN, PLP, or PHN was amitriptyline; the most common first-line treatment in people with TN was carbamazepine.
Hall and colleagues (2008)[17]	Prescribing Discontinuation	Retrospective cohort	UK 2002-2005	Size: 5,286 F: NR Age: NR	PHN TN PLP DN	People with PHN were less likely to be prescribed antidepressants or antiepileptics as first-line treatment compared to people with other NP diagnoses. People with PLP were more likely to be prescribed opioids as first-line treatment compared to people with other NP diagnoses.
Hall and colleagues (2013)[18]	Prescribing Discontinuation	Retrospective cohort	UK 2005-2010	Size: 102,386 F: NR Age: NR	PHN DN PLP NP back pain	People with DN were more likely to be prescribed antidepressants or anticonvulsants as first-line treatment compared to people with other NP diagnoses. People with neuropathic back pain were the most likely tc be prescribed tramadol.
Jacob and colleagues (2021)[69]	Prescribing	Retrospective cohort	Germany 2008-2017	Size: 48,324 F: 44.4% Age: 65.8	DN	Factors associated with being prescribed antiepileptics included: female gender, older age, having private insurance, or having type 1 diabetes.
Johnson and colleagues (2013)[46]	Prescribing Discontinuation	Retrospective cohort	USA 2005-2010	Size: 1,645 F: 59.5% Age: 63	PHN	People who had <150 mg/day of pregabalin or <1800 mg/day of gabapentin were more likely to have a shorter duration of therapy compared to those with ≥150 mg/day of pregabalin day or ≥1800 mg/day of gabapentin.

Johnston and colleagues (2014)[70]	Prescribing	Retrospective cohort	USA 2008-2009	Size: 30,428 F: 53.2% Age: 75.6	DN PHN	Compared to people with DN, people with PHN were more likely to have gabapentin, pregabalin, and topical pain medications. Compared to people with PHN, people with DN were more likely to have non-opioid analgesics.
Kato and colleagues (2023)[35]	Adherence Discontinuation	Retrospective cohort	Japan 2019-2021	Size: 4,138 F: 50.9% Age: 67.1	Peripheral NP	Mirogabalin dose titration was associated with better adherence and persistence compared to fixed-dose mirogabalin.
Knoerl and colleagues (2021)[25]	Prescribing	Non-randomised trial	USA 2018-2019	Size: 43 F: NR Age: NR	CIPN	There was no difference in the proportion of people being prescribed pain medication between the group that was treated with a decision support algorithm and the group treated with usual care, although the sample size may have been too small to detect any difference.
Koopman and colleagues (2010)[71]	Prescribing	Retrospective cohort	Netherlands 1996-2006	Size: 203 F: 62.1% Age: 54.3	Facial NP	Compared to people with TN, people with PHN were more likely to be prescribed medication according to the guidelines by the European Federation of Neurological Societies (EFNS). The most common medications as the first choice were antidepressants for people with PHN while the most common medications as the first choice were anticonvulsants for people with TN.
Kuo and colleagues (2016)[72]	Prescribing Discontinuation	Retrospective cohort	USA Puerto Rico 2006-2013	Size: 7,566 F: 54.7% Age: 64.4	DN	People who were prescribed combination pharmacotherapy were more likely to discontinue their treatment compared to those who were prescribed monopharmacotherapy.
Lakkad and colleagues (2023)[28]	Prescribing	Retrospective case-control	USA 2007-2015	Size: 7,116 F: 100% Age: 74.8	NP related to breast cancer treatment	Factors associated with being prescribed recommended medication as the first choice rather than opioids as the first choice included: white ethnicity, mental health disorders, diabetes, and dementia.
Margolis and colleagues (2017)[47]	Prescribing	Retrospective cohort	USA 2005-2014	Size: 14,655 F: 54.4% Age: 63.2	DN PHN	Compared to people with PHN, people with DN were more likely to be prescribed recommended medication as the first choice.
Martinez and colleagues (2014)[73]	Prescribing	Cross-sectional case-vignette survey	France 2012-2013	Size: 319 F: 20.4% Age: 52.3	DN CIPN PSN NP back pain	People with DN were more likely to be prescribed recommended NP medication compared to those with other NP diagnoses.

Mbrah and colleagues (2022)[74]	Prescribing	Retrospective case-control	USA 2016	Size: 69,160 F: 68.6% Age: NR	Any NP	Factors associated with being prescribed any pain medication included: female gender, anxiety, depression, multiple sclerosis, arthritis, and seizure disorder. Factors associated with not being prescribed any pain medication included: older age, cognitive impairment, Alzheimer's disease or dementia, cancer, coronary artery disease, fracture, and urinary tract disease.
Oladapo and colleagues (2012)[75]	Adherence	Retrospective cohort	USA 2003-2009	Size: 4,277 F: 72.4% Age: 53.2	DN	People were more adherent with duloxetine than TCAs, with TCAs than gabapentin, and with gabapentin than pregabalin.
Patil and colleagues (2015)[29]	Prescribing	Retrospective cohort	USA 1998-2008	Size: 666 F: 32.9% Age: 58.6	DN	People were more likely to be prescribed opioids as the first choice if they had diabetes-related organ damage or nephropathy.
Pérez and colleagues (2013)[76]	Prescribing	Prospective case-control	Spain 2005-2006	Size: 1,354 F: 49.8% Age: 59.3	DN PHN TN	Higher pain intensity, disability, depression severity, and worse health-related quality of life were associated with a higher likelihood of being prescribed pregabalin.
Pillay and colleagues (2015)[77]	Prescribing	Retrospective case-control	South Africa 2012-2014	Size: 130 F: 71.5% Age: 45.7	HIV-SN	People who had higher pain severity or lower CD4 T-cell count were more likely to be prescribed any pain medication.
Reed and colleagues (2013)[19]	Prescribing	Retrospective cohort	UK 2002-2011	Size: 6,779 F: 45.5% Age: 65.5	DN	People who were diagnosed with DN during 2002-2005 were more likely to be prescribed NSAIDs or opioids compared to people who were diagnosed with DN after 2005. People diagnosed with DN after 2005 were more likely to be prescribed anticonvulsants or SNRIs compared to people diagnosed with DN before 2005.
Reynolds and colleagues (2020a)[26]	Prescribing	RCT	USA 2016-2017	Size: 28 F: NR Age: NR	Peripheral NP	Factors associated with being prescribed recommended treatment included: male gender and being treated by a junior doctor.
Reynolds and colleagues (2020b)[11]	Prescribing Adherence	Retrospective cohort	USA 2001-2016	Size: 57,495 F: 54.2% Age: 64.7	Peripheral NP	Adherence to gabapentin was higher than adherence to pregabalin. A Adherence to venlafaxine was higher than adherence to duloxetine. Adherence to SNRIs tended to be higher than adherence to gabapentinoids. Higher cost of medication was associated with poorer adherence.

adosky and colleagues (2013)[78]	Prescribing	Cross-sectional	USA 2011	Size: 112 F: 52.5% Age: 61.1	DN	Higher pain intensity was associated with more pain medication prescriptions compared to lower pain intensity.
anchez and colleagues (2012)[39]	Adherence Discontinuation	Retrospective cohort	USA 2007-2009	Size: 6,459 F: 51.6% Age: 64.4	PHN DN	Compared to people prescribed <300 mg/day of pregabalin, people prescribed ≥300 mg/day of pregabalin had better adherence and persistence. Compared to people with PHN, people with DN had better adherence and persistence.
Shaparin and colleagues (2015)[27]	Discontinuation	Analysis of RCTs	USA Russia Argentina 2006-2012	Size: 556 F: 60.3% Age: 66.7	PHN	People were more likely to discontinue gabapentin if they had moderate or severe adverse events (e.g. dizziness, somnolence, nausea, or headache).
Sicras-Mainar and colleagues (2015)[20]	Prescribing Adherence Discontinuation	Retrospective cohort	Spain 2007-2013	Size: 1,369 F: 61.1% Age: 64.6	Peripheral NP	Compared to generic gabapentin, brand-name gabapentin was associated with better adherence and persistence.
Sicras-Mainar and colleagues (2019)[40]	Prescribing Adherence Discontinuation	Retrospective cohort	Spain 2014-2017	Size: 4,860 F: 61.3% Age: 59.9	Peripheral NP	Compared to generic pregabalin, brand-name pregabalin was associated with better adherence and persistence. Older age and being female were associated with better pregabalin treatment persistence.
utema and colleagues (2018)[36]	Adherence	RCT	Indonesia 2016-2017	Size: 62 F: 40.3% Age: 63.3	DN	In an RCT of people with DN who were aged 60 years or older, having a medicine reminder improved adherence.
Toth and colleagues (2014)[79]	Discontinuation	Prospective cohort	Canada NR	Size: 62 F: 58% Age: 51.9	Peripheral NP	Pain-related worrying was associated with a higher likelihood of discontinuation.
Udall and colleagues (2019)[80]	Prescribing	Cross-sectional	Brazil NR	Size: 209 F: 77.6% Age: 53	DN PHN CNP PTN PSN NP back pain	Compared to people with other NP diagnoses, people with PHN were the most likely to be prescribed any pain medication, antiepileptics, or SNRIs.
Wang and colleagues (2020)[41]	Discontinuation	Retrospective cohort	Taiwan 2012-2017	Size: 48,288 F: NR	DN PHN	Compared to people with PHN, people with DN were more likely to persist with pregabalin.

				Age: NR		
Winterbottom and colleagues (2006)[81]	Discontinuation	Retrospective cohort	USA 2002-2003	Size: 124 F: NR Age: NR	Any NP	Compared to usual practice, prescribing gabapentin through a clinical pharmacy consultation process was not associated with any difference in treatment persistence.
Wu and colleagues (2009)[37]	Prescribing Adherence	Retrospective case-control	USA 2003-2007	Size: 2,354 F: 57.8% Age: 61.8	DN	People who were prescribed >30mg/day duloxetine had better adherence than those who were prescribed ≤30mg/day duloxetine.
Wu and colleagues (2011)[82]	Prescribing Discontinuation	Retrospective cohort	USA 2004-2006	Size: 499 F: 55.3% Age: 54.8	DN	People who were prescribed duloxetine were less likely to use opioids compared to those who were prescribed other recommended NP medications.
Yang and colleagues (2015)[15]	Adherence Discontinuation	Retrospective cohort	USA 2005-2012	Size: 8,523 F: NR Age: NR	DN	People who were prescribed duloxetine had better adherence than those who were prescribed gabapentin or pregabalin. At 180 days, most people had discontinued their treatment in all groups.
Yeh and colleagues (2021)[34]	Adherence Discontinuation	Retrospective cohort	USA 2009-2014	Size: 5,186 F: 47.6% Age: 53	DN PHN NP related to SCI	The characteristics associated with better pregabalin adherence included: dose titration, older age, male gender, previous gabapentin or TCA use, and concomitant lidocaine use.
Zhao and colleagues (2011)[43]	Prescribing Adherence Discontinuation	Retrospective cohort	USA 2005-2007	Size: 2,573 F: 57.7% Age: 55.7	DN	People who were prescribed pregabalin were more likely to discontinue their treatment earlier and be less adherent compared to those who were prescribed duloxetine.
Zhao and colleagues (2012)[83]	Prescribing	Retrospective case-control	USA 2004-2008	Size: 2,694 F: 2.1% Age: 64.3	DN	Factors associated with being prescribed duloxetine rather than other recommended NP medications included: previous gabapentin use, previous TCAs use, previous venlafaxine use, previous opioid use, anxiety, substance abuse, cerebrovascular or peripheral vascular disease, and self-reported severe pain.

Table 2. Potential predictors of NP medication prescribing. Recommended medication: often similar to the list of recommended medications by Finnerup and colleagues (2015) [7] *but defined differently in each study (see Table S4 for precise lists); Non-opioid analgesic: non-steroidal anti-inflammatory drug, paracetamol, aspirin, or nefopam; Any pain medication: explained in Table S2; NP: neuropathic pain; DN: diabetic neuropathy; PHN: postherpetic neuralgia; CTS: carpal tunnel syndrome; TN: trigeminal neuralgia; PLP: phantom limb pain; PTN: post-traumatic neuropathic pain; PSN: post-surgical neuropathic pain, CNS: central nervous system; eGFR: estimated glomerular filtration rate; SEER: Surveillance, Epidemiology, and End Results. >: the predictors on the left side of this sign were associated with being prescribed the medications in the described subcategory compared to the potential predictor on the right side of this sign. =: the potential predictor on the left side of this sign was compared to the potential predictors on the right side of this sign, but the comparison was not statistically significant. #: conclusions from studies that included opioids in recommended treatment.*

	Recommended medication as the first choice	**Recommended medication at any point**
Increases the likelihood of being prescribed	White ethnicity > black or 'other' ethnicity[28] No previous opioid use for 3 months or longer[28] Previous antipsychotic use[28] Previous benzodiazepine use[28] Previous CNS depressant use[28] DN > PHN[47] Mental health disorder[28] Hemiplegia[28] Dementia[28] Diabetes[28] Rheumatologic disease[28] Breast cancer diagnosis year 2013 > 2007[28]	Diabetes[10, 28, 60] Depression[10, 60] Living in a more deprived region (Townsend index)[55, 56] Prescribed by physician > dispensed by a pharmacist[60] Treated by a pain specialist > not a pain specialist[10] Treated by a junior doctor > not a junior doctor[26] NP diagnosis > no NP diagnosis[73] DN > PHN[47] DN > other NP diagnosis[60, 73] No previous opioid use for 3 months or longer[28] Previous antipsychotic use[28] Previous benzodiazepine use[28] Previous CNS depressant use[28] Higher Charlson comorbidity score[10] Mental health disorder[28] Hemiplegia[28] Dementia[28] Rheumatologic disease[28] Breast cancer diagnosis year 2013 > 2007[28] Lower eGFR[55, 56] Higher low-density lipoprotein cholesterol[55, 56] Higher body mass index[55, 56] Lower alcohol intake > higher alcohol intake[60] # Anxiety and/or depression[58] # Pure NP > mixed pain[42] # PHN > TN[71]
No association	Geographic region (USA)[28]	Age[10, 26, 55, 56, 60]

	Urban location = not urban location[28] Marital status[28] Education[28] Household income[28] Previous NSAID use[28] Previous long-acting opioid use[28] Previous muscle relaxant use[28] Previous steroid use[28] Substance use disorder[28] Non-malignant pain conditions[28] Myocardial infarction[28] Stroke[28] Congestive heart failure[28] Peptic ulcer[28] Peripheral vascular disease[28] Chronic obstructive pulmonary disease[28] Liver disease[28] Breast cancer treatment type[28] Age at breast cancer diagnosis[28] SEER grade[28] SEER summary status[28] Hormone receptor status[28]	Sex [10, 26, 55, 60] White ethnicity = black ethnicity[10, 26, 28] Geographic region (USA)[28] Urban location = not urban location[28] Marital status[28] Insurance type[26] Smartset with best practice alert[26] Cervical/lumbar radiculopathy[60] SCI[60] PTN[60] PSN[60] Previous NSAID use[28] Previous long-acting opioid use[28] Previous muscle relaxant use[28] Previous steroid use[28] Substance use disorder[28] Non-malignant pain conditions[28] Myocardial infarction[28] Stroke[28] Congestive heart failure[28] Peptic ulcer[28] Peripheral vascular disease[28] Chronic obstructive pulmonary disease[28] Liver disease[28] Breast cancer treatment type[28] Age at breast cancer diagnosis[28] SEER grade[28] SEER summary status[28] Hormone receptor status[28] Diabetes duration[55] Diastolic blood pressure level[55] High-density lipoprotein cholesterol level[55] Total cholesterol level[55] Haemoglobin A1C level[55] Smoking status[60]
Inconsistent or unclear results	N/A	White ethnicity > Asian ethnicity[10, 26] White ethnicity > Hispanic ethnicity[10, 26]

		Education[10, 28] Household income[10, 28] Anxiety > no anxiety[10, 60] Systolic blood pressure level[55, 56]
	Opioids as the first choice	**Opioids at any point**
Increases the likelihood of being prescribed	Black or 'other' ethnicity > white ethnicity[28] Previous opioid use for 3 months or longer[28] No previous antipsychotic use[28] No previous benzodiazepine use[28] No previous CNS depressant use[28] PLP > DN[17, 18] PHN > DN[17, 18] Neuropathic back pain > PHN[18] PHN > TN[17] PLP > TN[17] DN > TN[17] No mental health disorder[28] No hemiplegia[28] No dementia[28] No diabetes[28] No rheumatologic disease[28] Diabetes with organ damage[28] Nephropathy[28] Breast cancer diagnosis year 2007 > 2013[28]	White ethnicity > Asian ethnicity[10, 68] Treated by a pain specialist[10] Prescribed by a physician > dispensed by a pharmacist[60] Concomitant generic pregabalin > brand-name pregabalin[20, 40] Previous opioid use for 3 months or longer[28] No previous antipsychotic use[28] No previous benzodiazepine use[28] No previous CNS depressant use[28] Low duloxetine compliance previously[37] PHN > DN[17, 18, 63, 70, 80] PHN > TN[17] PLP > TN[17] DN > TN[17] Neuropathic back pain > PHN[18] PSN > other NP diagnoses[80] No cervical/lumbar radiculopathy[60] Depression[10, 58, 60, 68] Anxiety[10, 58, 60, 68] Nephropathy[29] Diabetes with organ damage[29] No mental health disorder[28] No hemiplegia[28] No dementia[28] No rheumatologic disease[28] Breast cancer diagnosis year 2007 > 2013[28] Higher alcohol intake > lower alcohol intake[60] Smoking[60]
No association	Sex[29] Age[29] Geographic region (USA)[28, 29] Urban location = not urban location[28]	Age[10, 29, 60, 68, 70] Sex[10, 29, 60, 68] White ethnicity > Hispanic ethnicity[10, 68] White ethnicity = black ethnicity[10, 28, 68]

	Marital status[28] Education[28] Household income[28] Prescriber[29] PLP = PHN[17, 18] Neuropathic back pain = DN[18] Previous NSAID use[28] Previous long-acting opioid use[28] Insulin use[29] Previous muscle relaxant use[28] Substance use disorder[28] Non-malignant pain conditions[28] Myocardial infarction[28] Stroke[28] Congestive heart failure[28] Peptic ulcer[28] Peripheral vascular disease[28, 29] Cerebrovascular vascular disease[29] Cardiovascular disease[29] Chronic obstructive pulmonary disease[28] Liver disease[28] Metabolic disorders[29] Obesity[29] Retinopathy[29] Charlson comorbidity index[29] DN diagnosis year[19, 29] Breast cancer treatment type[28] Age at breast cancer diagnosis[28] SEER grade[28] SEER summary status[28] Hormone receptor status[28]	Geographic region (USA)[28, 29, 68] Urban location = not urban location[28] Marital status[28] Education[10, 28] Additional pharmacotherapy guideline information with a best practice alert[26] Concomitant pregabalin prescription[43, 65–67] Concomitant gabapentin prescription[57, 65, 66] Concomitant generic gabapentin = brand-name gabapentin[20] Dose titration of concomitant pregabalin[34] Previous NSAID prescription[28] Previous long-acting opioid prescription[28] Insulin use[29] SCI[60] Diabetes[10, 60] Peripheral vascular disease[28, 29] Cerebrovascular disease[29] Cardiovascular disease[29] Metabolic disorders[29] Obesity[29] Retinopathy[29] Substance use disorder[28] Non-malignant pain conditions[28] Myocardial infarction[28] Stroke[28] Congestive heart failure[28] Peptic ulcer[28] Chronic obstructive pulmonary disease[28] Liver disease[28] Breast cancer treatment type[28] Age at breast cancer diagnosis[28] SEER grade[28] SEER summary status[28] Hormone receptor status[28]
Inconsistent or unclear results	Older year of NP diagnosis > more recent NP diagnosis year[28]	Household income[10, 28] Insurance type[10, 29] Concomitant duloxetine prescription[61, 66, 82, 83] Mixed pain > pure NP[13, 42]

		Neuropathic back pain > DN[18, 80] Older year of NP diagnosis > more recent NP diagnosis year[28] Charlson comorbidity index[10, 29, 68]
	Non-opioid analgesics	**Any pain medication**
Increases the likelihood of being prescribed	Older age > younger age (in people <65 years old)[60, 70] Younger age > older age (in people >65 years old)[60, 70] Male > female[60] Concomitant generic gabapentin > brand-name gabapentin[20] Concomitant generic pregabalin > brand-name pregabalin[40] Dispensed by a pharmacist > prescribed by a physician[60] Mononeuropathy > other NP diagnosis[63] Neuropathic back pain > PHN[18, 80]	Younger age > older age (in people > 50 years old)[74, 77] Higher pain intensity[77, 78] Paraesthesia[77] Mixed pain > pure NP[42] Anxiety[58, 74] Depression[58, 74] No cognitive impairment[74] No Alzheimer's disease/dementia[74] No cancer[74] Multiple sclerosis[74] Arthritis[74] No fractures[74] Seizure disorder/epilepsy[74] No urinary tract infection[74] Low CD4 T-cell count[77] Does not reject care in a nursing home[74] Independent in daily activities[74]
No association	Concomitant gabapentin prescription[67] Concomitant duloxetine prescription[43, 66] Concomitant pregabalin prescription[43, 66, 67] Concomitant duloxetine compliance[37] SCI[60] Cervical/lumbar radiculopathy[60] DN = PHN[17, 18, 63, 70, 80] Mixed pain > pure NP[13, 42] Neuropathic back pain > DN[18, 80] PLP = PHN[17, 18] PLP = DN[17, 18] Anxiety[58, 60] Depression[58, 60] Diabetes[60] Alcohol intake[60]	Older age = younger age (in people <50 years old)[74, 77] Female > male[74, 77] Ethnicity[74] Education[77] Usual care = prescribing decision support algorithm[25] Type of HIV treatment[77] Number of pain sites[77] Numbness[77] Diabetes[74] Heart failure[74] Venous thromboembolism[74] Peripheral vascular or arterial disease[74] Cerebrovascular incidents[74] HIV[74] Osteoporosis[74]

	Smoking[60]	Current tuberculosis infection[77] Coronary artery disease[74]
Inconsistent or unclear results	Older year of NP diagnosis > more recent NP diagnosis year[19]	N/A

Table 3. Potential predictors of NP medication adherence and discontinuation. NP: neuropathic pain; DN: diabetic neuropathy; PHN: postherpetic neuralgia, TN: trigeminal neuralgia; TCA: tricyclic antidepressant, SSRI: selective serotonin reuptake inhibitors, SNRI: serotonin-norepinephrine reuptake inhibitors, COX: cyclooxygenase, EPO: exclusive provider organisation (only services in a specified network included), PPO: preferred provider organisation (also includes outside of network providers), POS: point-of-service, HMO: health maintenance organisation, IND: indemnity. >: the potential predictors on the left side of this sign were associated with a greater likelihood of being prescribed the medications in the described subcategory compared to the potential predictor on the right side of this sign. =: The potential predictor on the left side of this sign was compared to the potential predictors on the right side of this sign, but the comparison was not statistically significant. Vs: The potential predictor on the left side of this sign was compared to the potential predictors on the right side of this sign, and it was not possible to identify any trend. Potential predictors following a colon (:) were specifically investigated in the subgroup indicated by the word before the colon.

	Adherence	**Discontinuation**
Increases the likelihood	Older (until 74 years) > younger[11, 34, 35, 37, 38] White ethnicity > non-white ethnicity[11] North Central USA > South USA[11, 34, 38] Middle Atlantic USA > West South-Central USA[11, 34, 38] EPO insurance > PPO insurance[11, 34] POS insurance > PPO insurance[11, 34] Lower medication cost to the patient[11] Duloxetine > pregabalin[11, 15, 43, 75] Duloxetine > gabapentin[11, 15, 33] Gabapentin > pregabalin[11, 15, 33] Venlafaxine > TCAs[33] Duloxetine > TCAs[75] Duloxetine dose above 30 mg[38] Dose titration[34, 35] Brand-name medication > generic medication[20, 40] Medicine reminder[36] Pregabalin: concomitant lidocaine[34] Pregabalin: previous gabapentin[34] Pregabalin: previous TCAs[34] DN > PHN[39]	South USA > West USA[34] TCAs > other antidepressants[17, 42] SNRIs > SSRIs[42] Amitriptyline > gabapentin[79] Pregabalin > duloxetine[15, 43] Short-acting opioids > long-acting opioids[42] COX2 inhibitors > COX1 inhibitors[42] Generic medication > brand-name medication[20, 40] Duloxetine dose 30 mg > above 30 mg[38] 2nd-line medication > 1st/3rd-line medication[14] Combination pharmacotherapy > monopharmacotherapy[72] Pregabalin: no concomitant medication > concomitant SNRIs[34] Pregabalin: no concomitant medication > concomitant tramadol[34] Pregabalin: no concomitant medication > concomitant opioids[34] Short acting opioids: concomitant medication other than duloxetine[61, 82] Pregabalin: no previous gabapentin use > previous gabapentin use[34] Pregabalin: previous tramadol use > no previous tramadol use[34] Mirogabalin: no previous NP medication > previous NP medication[35] Experiencing clinically significant pain relief from NP medication[40] Experiencing moderate adverse events from NP medication[27]

	No migraine > migraine[38]	Experiencing severe adverse events from NP medication[27] Nausea as an adverse event from NP medication[27] Somnolence as an adverse event from NP medication[27] Headache as an adverse event from NP medication[27] Dizziness as an adverse event from NP medication[27] PHN > DN[17, 18, 31, 39, 41] PHN > PLP[17, 18, 31] Neuropathic back pain > DN[18] PLP > neuropathic back pain[18] PHN > neuropathic back pain[18] Lower Charlson comorbidity index[34, 35] Pain-related worrying[79] Lower activity level[79] Not using praying or hoping as coping behaviours[79] Treatment department other than neurology[35]
No association	Sex[11, 34, 35, 38] Education[11] Household income[11] HMO insurance = PPO insurance[11, 34] IND insurance = PPO insurance[11, 34] High-deductible health plan = PPO insurance[11, 34] Venlafaxine > duloxetine[11] Initial dose of NP medication[34, 35] Pregabalin: concomitant/previous SNRIs[34] Pregabalin: concomitant gabapentin[34] Pregabalin: previous lidocaine[34] Pregabalin: concomitant/previous opioids[34] Pregabalin: concomitant/previous tramadol[34] Mirogabalin: any previous NP medication[35] Pain duration[35] Fibromyalgia[38] Osteoarthritis[38] Rheumatoid arthritis[38] Psoriatic arthropathy[38] Lower back pain[38] CKD classification based on eGFR[35] Renal function based on CrCL[35]	Age[27, 34, 35, 40, 79] Sex[27, 34, 35, 40, 79] Ethnicity[27] Insurance type[34] Clinical pharmacy consult algorithm[81] Pregabalin: ≥300 mg/day > <300 mg/day[39] Pregabalin: ≥150 mg/day > <150 mg/day[46] Gabapentin: ≥1800 mg/day > <1800 mg/day[46] Initial dose of NP medication[34, 35] No dose titration > dose titration[34, 35] Experiencing mild adverse events from NP medication[27] Pain intensity[27, 79] PLP = DN[17, 18, 31] TN = DN[17, 31] TN = PHN[17, 31] TN = PLP[17, 31] Mixed pain > pure NP[13, 42] Mirogabalin: previous gabapentin use = no previous gabapentin use[35] Pregabalin: previous opioid use = no previous opioid use[34] Pregabalin: previous lidocaine use = no previous lidocaine use[34] Pregabalin: previous TCA use = no previous TCA use[34] Pregabalin: previous SNRI use = no previous SNRI use[34]

	Treatment department[35] Hospital visits[34, 35]	EQ-5D disability index score[79] BPI score[27] CKD classification based on eGFR[35] Renal function based on CrCL[35] Hospital visits[34, 35]
Inconsistent or unclear results	Pregabalin dose[39] Lower Charlson comorbidity index[34, 35]	Gabapentin > pregabalin[15, 44–46, 79] TCAs > antiepileptics[17, 42, 79] Opioids vs TCAs[17, 42] Opioids vs antiepileptics[17, 42] Pain duration[35, 79]


COX-2 Inhibitors 12 8 1 0 20 43 46 24 34 14 21 11 12
COX-1 Inhibitors 0 -4 -11 -12 9 31 35 12 22 2 9 -1 -12
Any NSAIDs 1 -3 -10 -11 10 32 36 13 23 3 10 1 -11
Gabapentin -9 -13 -20 -21 0 22 26 3 13 -7 -10 -9 -21
Carbamazepine -2 -6 -13 -14 7 29 33 10 20 7 -3 -2 -14
Any AEDs -22 -26 -33 -34 -13 9 13 -10 -20 -13 -23 -22 -34
Any SNRIs -12 -16 -23 -24 -3 19 23 10 -10 -3 -13 -12 -24
Any SSRIs -35 -39 -46 -47 -26 -4 -23 -13 -33 -26 -36 -35 -46
Any second generation antidepressants -31 -35 -42 -43 -23 4 -19 -9 -29 -22 -32 -31 -43
LAOs -9 -12 -20 -20 23 26 3 13 -7 0 -10 -9 -20
SAOs 12 8 1 20 43 47 24 34 14 21 11 12 0
Any Opioids 11 7 -1 20 42 46 23 33 13 20 10 11 -1
Amitriptyline 4 -7 -8 12 35 39 16 26 6 13 3 4 -8
Any TCAs -4 -11 -12 9 31 35 12 22 2 9 -1 0 -12
Any TCAs
Amitriptyline
Any Opioids
SAOs
LAOs
Any second generation antidepressants
Any SSRIs
Any SNRIs
Any AEDs
Carbamazepine
Gabapentin
Any NSAIDs
COX-1 Inhibitors
COX-2 Inhibitors
Mean Difference
25
0
-25


Local anaesthetics
Rubefacients/other topical antirheumatics
Opioids
Non-opioid analgesics
Other antidepressants
TCAs
Antiepileptics
0.5 0.48 0.76 0.58 0.63 0.69
0.72 0.7 1.09 0.84 0.91 1.44
0.79 0.77 1.21 0.93 1.1 1.59
0.85 0.83 1.3 1.08 1.19 1.72
0.65 0.64 0.77 0.83 0.91 1.32
1.02 1.56 1.2 1.29 1.43 2.06
0.98 1.53 1.17 1.27 1.4 2.02
Antiepileptics
TCAs
Other antidepressants
Non-opioid analgesics
Opioids
Rubefacients/other topical antirheumatics
Local anaesthetics
Odds Ratio
2.0
1.5
1.0
0.5


Identification
Records from databases (n = 9453)
Embase (n = 4140)
PubMed (n = 2618)
Web of Science (n = 2136)
CINAHL (n = 559)
Records from reference lists of included studies (n = 6)
Duplicates removed (n = 3030)
Duplicates removed by Covidence (n = 2995)
Duplicates removed manually (n = 35)
Screening
Titles/abstracts screened (n = 6429)
Records excluded (n = 6279)
Records assessed for eligibility (n = 150)
Records excluded (n = 90)
No relevant outcomes (n=12)
Sample not specific to NP (n = 17)
No predictors (n = 22)
Irrelevant medications (n=4)
Wrong study design (n=1)
RCT: discontinuation by mediation (n = 6)
Not a full text article (n = 26)
Not in English (n = 1)
No data to support relevant statements (n = 1)
Included
Studies included in review (n = 60)